224 related articles for article (PubMed ID: 15919721)
1. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function.
Li W; Cavasotto CN; Cardozo T; Ha S; Dang T; Taneja SS; Logan SK; Garabedian MJ
Mol Endocrinol; 2005 Sep; 19(9):2273-82. PubMed ID: 15919721
[TBL] [Abstract][Full Text] [Related]
2. Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity.
He B; Gampe RT; Hnat AT; Faggart JL; Minges JT; French FS; Wilson EM
J Biol Chem; 2006 Mar; 281(10):6648-63. PubMed ID: 16365032
[TBL] [Abstract][Full Text] [Related]
3. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
Duff J; McEwan IJ
Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
[TBL] [Abstract][Full Text] [Related]
4. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
5. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.
Quigley CA; Tan JA; He B; Zhou ZX; Mebarki F; Morel Y; Forest MG; Chatelain P; Ritzén EM; French FS; Wilson EM
Mech Ageing Dev; 2004; 125(10-11):683-95. PubMed ID: 15541764
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the molecular consequences of different mutations at residue 754 and 690 of the androgen receptor (AR) and androgen insensitivity syndrome (AIS) phenotype.
Tadokoro R; Bunch T; Schwabe JW; Hughes IA; Murphy JC
Clin Endocrinol (Oxf); 2009 Aug; 71(2):253-60. PubMed ID: 19178528
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the amino-terminal domain of the human androgen receptor may be associated with partial androgen insensitivity and impaired transactivation in vitro.
Holterhus PM; Werner R; Struve D; Hauffa BP; Schroeder C; Hiort O
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):457-63. PubMed ID: 16151980
[TBL] [Abstract][Full Text] [Related]
9. Molecular cell biology of androgen receptor signalling.
Bennett NC; Gardiner RA; Hooper JD; Johnson DW; Gobe GC
Int J Biochem Cell Biol; 2010 Jun; 42(6):813-27. PubMed ID: 19931639
[TBL] [Abstract][Full Text] [Related]
10. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
11. Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients.
Kawate H; Wu Y; Ohnaka K; Tao RH; Nakamura K; Okabe T; Yanase T; Nawata H; Takayanagi R
J Clin Endocrinol Metab; 2005 Nov; 90(11):6162-9. PubMed ID: 16118342
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome.
Ahmed SF; Cheng A; Dovey L; Hawkins JR; Martin H; Rowland J; Shimura N; Tait AD; Hughes IA
J Clin Endocrinol Metab; 2000 Feb; 85(2):658-65. PubMed ID: 10690872
[TBL] [Abstract][Full Text] [Related]
13. A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions.
Deeb A; Jääskeläinen J; Dattani M; Whitaker HC; Costigan C; Hughes IA
J Clin Endocrinol Metab; 2008 Oct; 93(10):3691-6. PubMed ID: 18697867
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of a novel androgen receptor mutation, Q902K, in an individual with partial androgen insensitivity.
Umar A; Berrevoets CA; Van NM; van Leeuwen M; Verbiest M; Kleijer WJ; Dooijes D; Grootegoed JA; Drop SL; Brinkmann AO
J Clin Endocrinol Metab; 2005 Jan; 90(1):507-15. PubMed ID: 15486055
[TBL] [Abstract][Full Text] [Related]
15. Promoter-dependent activity on androgen receptor N-terminal domain mutations in androgen insensitivity syndrome.
Tadokoro-Cuccaro R; Davies J; Mongan NP; Bunch T; Brown RS; Audi L; Watt K; McEwan IJ; Hughes IA
Sex Dev; 2014; 8(6):339-49. PubMed ID: 25500996
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor gene mutations in androgen insensitivity syndrome cause distinct patterns of reduced activation of androgen-responsive promoter constructs.
Werner R; Schütt J; Hannema S; Röpke A; Wieacker P; Hiort O; Holterhus PM
J Steroid Biochem Mol Biol; 2006 Sep; 101(1):1-10. PubMed ID: 16930995
[TBL] [Abstract][Full Text] [Related]
17. The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.
Mukherjee S; Cruz-Rodríguez O; Bolton E; Iñiguez-Lluhí JA
J Biol Chem; 2012 Sep; 287(37):31195-206. PubMed ID: 22829593
[TBL] [Abstract][Full Text] [Related]
18. Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
Grosdidier S; Carbó LR; Buzón V; Brooke G; Nguyen P; Baxter JD; Bevan C; Webb P; Estébanez-Perpiñá E; Fernández-Recio J
Mol Endocrinol; 2012 Jul; 26(7):1078-90. PubMed ID: 22653923
[TBL] [Abstract][Full Text] [Related]
19. The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity.
Ghali SA; Gottlieb B; Lumbroso R; Beitel LK; Elhaji Y; Wu J; Pinsky L; Trifiro MA
J Clin Endocrinol Metab; 2003 May; 88(5):2185-93. PubMed ID: 12727974
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.
Yeh S; Sampson ER; Lee DK; Kim E; Hsu CL; Chen YL; Chang HC; Altuwaijri S; Huang KE; Chang C
J Formos Med Assoc; 2000 Dec; 99(12):885-94. PubMed ID: 11155740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
